Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

    NEXT STORY
    Shire plc : Shire Announces Sale of Oncology Business to Servier for $2.4 Billion
    PREV STORY
    Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Hydronephrosis Therapies Market 2019-2023: Market to Grow at a CAGR of 9.14%

    author_avatar
    NASDAQ Market News

    Ventilators Market by Mobility, Type, Mode, Interface, End-User Covid-19 Impact – Global Forecast to 2025

    author_avatar
    NASDAQ Market News

    Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights issue

    author_avatar
    NASDAQ Market News